Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a world leader in life science research and clinical diagnostic products, is ramping up production of its Platelia SARS-CoV-2 Total Ab test, a blood immunoassay test to determine if an individual has developed antibodies against SARS-CoV-2, the virus associated with COVID-19.
Bio-Rad’s SARS-CoV-2 test is also CE marked for Europe, and, after validation by the CNR of the French National Reference Center, listed among the serological tests approved by the French government for the detection of SARS- CoV-2.
Bio-Rad’s SARS-CoV-2 Total Ab test can help clinicians identify if an individual has been infected with SARS-CoV-2 and has therefore developed an immune response against the virus.
“We are pleased to have developed our SARSCoV-2 Total Ab test to support the diagnosis of COVID-19 and to screen populations. “Said Jean-François Mouscadet, PhD, Associate VP, Bio-Rad Clinical Diagnosis, Europe
“The total antibody approach allows the detection of antibodies in the majority of patients 8 days after the onset of symptoms, unlike an approach using IgG only. ” he added.
The SARS-CoV-2 Total Ab test was designed to be used manually or on an automated immunoassay platform, such as Bio-Rad’s EVOLIS system, which offers high throughput processing and sample traceability.
Bio-Rad launched the test in late April, which was the first serological test to receive emergency marketing authorization from the United States Food and Drug Administration (FDA).
– .
